BioMarin Shoots Up Ahead of FDA Panel

BioMarin Shoots Up Ahead of FDA Panel

BioMarin Pharmaceutical Inc.'s (BMRN – Analyst Report) stock price increased almost 8% when the U.S. Food and Drug Administration (FDA) released upbeat briefing documents ahead of the review by its Endocrinologic and Metabolic Drugs Advisory 

3
Like
Save

Comments

Write a comment

*